Black Women Experience More Treatment Modifications Than White Women With Breast Cancer


Black patients may have poorer outcomes during breast cancer treatment than White patients.

Breast cancer treatment in the neoadjuvant setting may lead to more modification in Black patients than White patients, according to a presentation from the 2021 San Antonio Breast Cancer Symposium (SABCS).

The higher incidence of treatment modifications may lead to poorer outcomes in this patient population, according to the study authors.

The results from this proof-of-concept study demonstrated that the use of a multiscale biophysical modeling platform may help identify what treatment outcomes may look like before clinicians and patients decide whether to modify the current treatment.

Researchers conducted a retrospective review of 173 patients who had received neoadjuvant therapy from January 2010 through March 2020 and separated the patients into 2 cohorts: 114 who received a scheduled regimen (SR) and 59 who received a modified regimen (MR)Although there were nearly double the amount of patients in the SR group than in the MR cohort, Black patients accounted for 59% of the MR cohort.

In the MR group, a significantly lower proportion of patients achieved a pathologic complete response (pCR) compared with the SR group (Odds ratio, 0.44; P = .03). Moreover, similar to what has been observed in other studies, 42% of Black patients had treatment interruptions compared with 25% of White patients.

“During neoadjuvant therapy in breast cancer, treatment interruptions may impact rates of pathologic complete response and ultimately increase risk of recurrence,” the study authors wrote in their poster at SABCS.

Six patients (10%) had early discontinuation of doxorubicin and cyclophosphamide, 25 patients (42%) had an early discontinuation of a taxane therapy, 7 patients (12%) had an anti-HER2 therapy discontinued, and 21 patients (36%) had dose reductions throughout their therapy.

The study authors observed a pCR rate of 42% in the SR group and 20% in the MR group.

Utilizing the multiscale biophysical modeling platform, known as TumorScope, the researchers were able to use data from patients in the MR group and simulate what responses to treatment may have been if patients had received the full dose of their treatment uninterrupted. The simulation demonstrated that without treatment interruption, 10 additional patients (5.6%) would have been able to achieve a pCR. In the simulation, 100% of patients receiving SR had a complete response in comparison to 81.7% of those who would experience treatment interruptions.

TumorScope was previously evaluated in a separate study to determine its effectiveness and was used in several other studies and analyses presented at this year’s SABCS.2 According to the researchers of this study, the results show that TumorScope can be used to estimate the impact of variable dosing before clinicians decide to interrupt a patient’s treatment. Furthermore, researchers believe that TumorScope can evaluate individual treatments being considered for this patient population to support de-escalation of therapy ahead of time but note that further study is needed.


1. Pandey T, Pfeiffer J, Braun E, at al. Assessing the impact of treatment interruptions during neoadjuvant therapy in early stage breast cancer. Poster presented at: 2021 San Antonio Breast Cancer Symposium. December 7-10, 2021. San Antonio, Texas. P1-08-21

2. SimBioSys Presents New Studies on its Precision Medicine Software Platform at the 2021 San Antonio Breast Cancer Symposium. Press Release. December 1st, 2021. Accessed December 8th, 2021.

Related Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Related Content